BIT/BITO .. HCV/HIV drug market . Largely ignored so plenty of time to DYOR . Results due 8/12 .
Should be on your radar people .
$15m m/c , full results of phase 2a due 8/12 , short term in the money ( just ) options .
This stock can genuinely be compared with other stocks whose values range from $400m to $11B . I am not joking . The drug has already been deemed non toxic and more effective than the standard of care in patients who respond to the drug . The unknown is the response RATE .
